Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Hamadani, Mehdi
Graham, Christopher N.
Liao, Laura
Zhang, Katherine H.
Strat, Hannah
Ungar, David
Ai, Weiyun Z.
Chen, Lei
Carlo-Stella, Carmelo
机构：
[1] BMT & Cellular Therapy Program, Med Coll Wisconsin, Milwaukee, WI USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] ADC Therapeut Inc, New Providence, NJ USA
[4] ADC Therapeut Amer Inc, Clin Dev, Murray Hill, NJ USA
[5] Univ Calif San Francisco, Div Hematol & Oncol, Dept Med, San Francisco, CA USA
[6] Humanitas Res Hosp, Rozzano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
    Longcor, J.
    Oliver, K.
    Friend, J.
    Callandar, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
  • [32] Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Spira, Alexander
    Zhou, Xiaolei
    Chen, Lei
    Gnanasakthy, Ari
    Wang, Luqiang
    Ungar, David
    Curiel, Rafael
    Liao, Laura
    Radford, John
    Kahl, Brad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 158 - 168
  • [33] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [34] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [35] New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment
    Tauveron-Jalenques, Urbain
    Bay, Jacques-Olivier
    BULLETIN DU CANCER, 2023, 110 (05) : 476 - 477
  • [36] Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
    Alderuccio, Juan Pablo
    Kuker, Russ A.
    Reis, Isildinha M.
    Nachiappan, Muthiah
    Kahl, Brad S.
    Hamadani, Mehdi
    Ai, Weiyun Z.
    Radford, John
    Solh, Melhem
    Ardeshna, Kirit M.
    Hess, Brian T.
    Lunning, Matthew A.
    Zinzani, Pier Luigi
    Stathis, Anastasios
    Carlo-Stella, Carmelo
    Yu, Eric
    Caimi, Paolo F.
    Kwon, Deukwoo
    Lossos, Izidore S.
    Yang, Fei
    Moskowitz, Craig H.
    BLOOD, 2022, 140 : 6650 - 6652
  • [37] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
    Ahmed, Nausheen
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1313 - 1320
  • [39] R-IPI as a predictor of survival in patients with diffuse large cell B-cell lymphoma (DLBCL) treated with R-chop chemotherapy
    Siddiqui, M.
    Johnston, P. B.
    Micallef, I. N.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Ristow, K.
    Witzig, T. E.
    Porrata, L. F.
    ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [40] Estimation of Long-Term Survival with Tafasitamab plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Salles, Gilles
    Goswami, Budhaditya
    Bagnardi, Vincenzo
    Dey, Debarshi
    Winderlich, Mark
    Ambarkhane, Sumeet
    Huang, Dan
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
12345